Clinical Trial Update: A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease [Phase 2]

View source ↗

Summary

Novartis is conducting a Phase 2 trial to evaluate the efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still's disease; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Still Disease

Drugs mentioned

• MAS825

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Still´s Disease | Phase 2 | Status: RECRUITING